Qiagen Stock - Deutsche Bank reiterates Buy rating
Published on 06/17/2026 at 16:15 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 16:14 CET. Details in the imprint.
Qiagen (NL0012169213) remains on Deutsche Bank’s buy list after the bank reiterated its Buy rating on the diagnostics specialist. The reaffirmed stance, highlighted in an analyst note referenced by MarketScreener, underlines upside potential despite a muted share performance recently.
All news and data on Qiagen stock
Key analyst views, fundamentals and price data on Qiagen stock are bundled on the topic page and the company’s investor-relations site.
Deutsche Bank stays positive
According to a recent Deutsche Bank update summarized by MarketScreener, the bank reiterates its Buy rating on Qiagen stock and confirms its positive stance on the company’s medium-term prospects. MarketScreener cites Deutsche Bank’s reaffirmed Buy recommendation.
The note points to Qiagen’s portfolio across molecular diagnostics and life-science tools as a driver of structural growth and underpins an average analyst target price around $43.82, compared with a recent U.S. close a little above $37. MarketScreener’s consensus overview lists the average target and rating mix.
How consensus on Qiagen is shaping up
Qiagen is covered by a broad analyst community, with the latest consensus still skewed toward positive recommendations such as Buy and Overweight, while a minority of houses advise Hold. The consensus compilation shows both rating distribution and target range.
The average 12-month price target near $43-44 implies mid-single-digit upside from the most recent U.S.-traded level, though the spread between the highest and lowest targets underlines how differently houses gauge post-pandemic diagnostics demand.
The product behind the stock
Qiagen generates most of its revenue with so-called Sample to Insight solutions that prepare, amplify and analyze DNA, RNA and proteins, including flagship product lines such as QIAamp sample preparation kits and the QIAcuity digital PCR platform for high-precision molecular testing.
Where the stock trades today
Qiagen shares (NL0012169213) last traded on the New York Stock Exchange at $37.22 as of 06/16/2026, 22:00 ET.
Key facts on Qiagen stock
- Company: QIAGEN N.V.
- ISIN: NL0012169213
- WKN: A2DKCH
- Ticker: QGEN
- Venue: Nasdaq
- Price (as of 06/16/2026, 22:00 ET): 37.22 USD
- Market cap: 7.67 billion USD (as of 06/2026)
- Sector / Industry: Health Care - Life Sciences Tools & Services
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
